In fact, overexpression of Bcl-2 and Bcl-xL is observed in several cancers, including hematologic malignancies, as well as a range of solid tumors, including nasopharyngeal, colorectal, prostate, and breast cancer [5-7]. Here, BCL2L1 is linked to breast cancer.